Unsolved issues of The Efficacy and Safety of Edoxaban.
作者信息
Drabik Leszek, Undas Anetta
机构信息
Department of Pharmacology, Jagiellonian University Medical College, Krakow, Poland.
Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland.
出版信息
Anatol J Cardiol. 2021 Jun;25(6):460. doi: 10.5152/AnatolJCardiol.2021.81410.
Abstract
摘要
相似文献
1
Unsolved issues of The Efficacy and Safety of Edoxaban.依度沙班有效性与安全性的未解决问题。
Anatol J Cardiol. 2021 Jun;25(6):460. doi: 10.5152/AnatolJCardiol.2021.81410.
2
Efficacy and Safety of Edoxaban in Nonvalvular Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials.依度沙班用于非瓣膜性心房颤动的疗效与安全性：一项随机对照试验的荟萃分析
J Stroke Cerebrovasc Dis. 2015 Dec;24(12):2710-9. doi: 10.1016/j.jstrokecerebrovasdis.2015.07.026. Epub 2015 Aug 29.
3
Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction).依度沙班与华法林治疗胃肠道出血的比较：ENGAGE AF-TIMI 48试验（房颤患者使用新一代Xa因子有效抗凝——心肌梗死溶栓治疗48）结果
Circ Cardiovasc Qual Outcomes. 2018 May;11(5):e003998. doi: 10.1161/CIRCOUTCOMES.117.003998.
4
Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.21105 例心房颤动随机分组至依度沙班与华法林治疗的脑血管事件：房颤患者中新型 Xa 因子抗凝剂的有效抗凝作用-心肌梗死溶栓 48 研究
Stroke. 2014 Aug;45(8):2372-8. doi: 10.1161/STROKEAHA.114.006025. Epub 2014 Jun 19.
5
Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial.依房颤患者疾病负担评估比较依度沙班与华法林的疗效和安全性：来自 ENGAGE AF-TIMI 48 试验的见解。
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(3):167-175. doi: 10.1093/ehjcvp/pvz061.
6
Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial.基于ENGAGE AF-TIMI 48试验结果，比较依度沙班与华法林在房颤患者中与心血管和出血相关的住院率
Circ Cardiovasc Qual Outcomes. 2020 Nov;13(11):e006511. doi: 10.1161/CIRCOUTCOMES.120.006511. Epub 2020 Nov 5.
7
Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial.华法林或依度沙班抗凝治疗的房颤患者颅内出血：来自 ENGAGE AF-TIMI 48 随机试验的深入分析。
J Clin Neurosci. 2021 Apr;86:294-300. doi: 10.1016/j.jocn.2020.10.036. Epub 2021 Jan 12.
8
Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.依度沙班与依诺肝素 - 华法林用于房颤复律患者的疗效比较（ENSURE - AF）：一项随机、开放标签的3b期试验。
Lancet. 2016 Oct 22;388(10055):1995-2003. doi: 10.1016/S0140-6736(16)31474-X. Epub 2016 Aug 30.
9
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.依度沙班剂量、浓度、抗 Xa 因子活性与结局的相关性：来自随机、双盲 ENGAGE AF-TIMI 48 试验的数据分析。
Lancet. 2015 Jun 6;385(9984):2288-95. doi: 10.1016/S0140-6736(14)61943-7. Epub 2015 Mar 11.
10
Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial.在 ENGAGE AF-TIMI 48 试验中，各出血量表事件的比较。
Circulation. 2019 Nov 26;140(22):1792-1801. doi: 10.1161/CIRCULATIONAHA.119.041346. Epub 2019 Oct 10.
引用本文的文献
1
Effect of edoxaban compared with other oral anticoagulants for stroke prevention in patients with atrial fibrillation: A meta-analysis.依度沙班与其他口服抗凝药相比在预防心房颤动患者卒中方面的效果：一项荟萃分析。
Heliyon. 2023 Nov 3;9(11):e21740. doi: 10.1016/j.heliyon.2023.e21740. eCollection 2023 Nov.
本文引用的文献
1
The efficacy and safety of edoxaban versus warfarin in preventing clinical events in atrial fibrillation: A systematic review and meta-analysis.依度沙班与华法林预防房颤临床事件的疗效和安全性：系统评价和荟萃分析。
Anatol J Cardiol. 2021 Feb;25(2):77-88. doi: 10.14744/AnatolJCardiol.2020.18049.
2
Trends in antithrombotic management of patients with atrial fibrillation. A report from the Polish part of the EURObservational Research Programme - Atrial Fibrillation General Long-Term Registry.心房颤动患者抗栓治疗趋势。EURObservational Research Programme - Atrial Fibrillation General Long-Term Registry 波兰部分的报告。
Pol Arch Intern Med. 2020 Mar 27;130(3):196-205. doi: 10.20452/pamw.15157. Epub 2020 Jan 24.
3
Bleeding in anticoagulated patients with atrial fibrillation: practical considerations.抗凝治疗的心房颤动患者出血：实用注意事项。
Pol Arch Intern Med. 2020 Jan 31;130(1):47-58. doi: 10.20452/pamw.15136. Epub 2020 Jan 14.
4
Efficacy and Safety of Edoxaban in Nonvalvular Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials.依度沙班用于非瓣膜性心房颤动的疗效与安全性：一项随机对照试验的荟萃分析
J Stroke Cerebrovasc Dis. 2015 Dec;24(12):2710-9. doi: 10.1016/j.jstrokecerebrovasdis.2015.07.026. Epub 2015 Aug 29.
5
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.新型口服抗凝剂与华法林治疗心房颤动患者的疗效和安全性比较：随机试验的荟萃分析。
Lancet. 2014 Mar 15;383(9921):955-62. doi: 10.1016/S0140-6736(13)62343-0. Epub 2013 Dec 4.
Zotero 插件